Wockhardt Becomes First Indian Drug Maker to Receive EMR

Law360, New York (December 28, 2003, 12:00 AM EST) -- Wockhardt Ltd. became the first domestic Indian drug maker to secure an exclusive marketing right last week after the Controller General of Patents and Trademarks granted an EMR for its topical anti-bacterial drug Nadoxin (Nadifloxacin).

Nadoxin is a treatment against a wide spectrum of topical bacterial infections. A post-marketing surveillance study conducted on 696 patients across the country has established a 99% success rate for Nadoxin, the company said.

Wockhardt is only the second pharmaceutical company to receive an EMR after Novartis secured rights for its...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.